



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stephanopolous *et al.*

Serial No: 10/076,106

Filed: February 13, 2002

For: DYNAMIC WHOLE GENOME
SCREENING METHODOLOGY
AND SYSTEMS

Attorney Docket No. MIN-P01-038

Art Unit: 1639


Examiner: Epperson, Jon D.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

November 17, 2003

Date of Signature
and of Mail Deposit


Joanne Ryan

Mail Stop Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

AUG 25 2004

TECH CENTER 1600/2300

REPLY TO SEQUENCE LISTING OFFICE ACTION

Sir:

This amendment is being filed in reply to the outstanding Office Communication, mailed October 29, 2003, in connection with the above application.

The Office Communication asserts that the application contains sequence disclosures but fails to comply with the requirement of 37 CFR 1.821 – 1.825, because the application allegedly does not contain, as a separate part of the disclosure on paper copy, a “Sequence Listing” as required by 37 CFR 1.821(c). The Office Communication also specifically points to the nucleic acid sequence on page 14, line 25, and requests Applicants to re-check the entire specification, and submit an initial CRF copy of the “Sequence Listing.”

Applicants submit that a Sequence Listing containing the nucleic acid sequence disclosed on page 14, line 25 was filed electronically on October 7, 2002, the receipt of which was acknowledged by OIPE. Applicants hereby submit a copy of the documents related to the

electronic filing of the Sequence Listing, together with a copy of the return postcard bearing an OIPE stamp date of October 16, 2002. In addition, Applicants submit a copy of the PAIR print-out, indicating that "CRF is good technically / entered into database" on October 8, 2002.

Finally, Applicants have re-checked the entire specification, and found no other sequences that should be included in the Sequence Listing as required by 37 CFR 1.821-1.825. Applicants respectfully request the Examiner to point out any additional sequences that should be included in the Sequence Listing.

CONCLUSION

For the foregoing reasons, Applicants respectfully request reconsideration and withdrawal of the pending objections.


Applicants believe that the claims are now in condition for allowance and early notification to this effect is earnestly solicited. Any questions arising from this submission may be directed to the undersigned at (617) 951-7000.

If there are any other fees due in connection with the filing of this submission, please charge the fees to our **Deposit Account No. 18-1945**. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit account.

Respectfully Submitted,

Date: November 17, 2003

Customer No: 28120
Docketing Specialist
Ropes & Gray LLP
One International Place
Boston, MA 02110
Phone: 617-951-7000
Fax: 617-951-7050



Yu Lu, Ph.D.
Reg. No. 50,306